• Triplet Regimen Boosts Survival in Metastatic Melanoma, but at a Cost

    13 days ago - By Medscape

    For patients with metastatic melanoma, triplet therapy with atezolizumab and vemurafenib plus cobimetinib provides significant survival benefits, but the regimen may not be cost-effective, researchers say.
    Reuters Health Information
    Read more ...